Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Study participant must be at least 19 years of age at the time of signing the informed consent~* Study participant must be a Korean adult with a diagnosis of moderate to severe psoriasis (PSO)~* Study participant must have had plaque PSO for at least 6 months prior to the Screening Visit~* Study participant must have Psoriasis Area and Severity Index (PASI) ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5-point scale~* Study participant must be a candidate for systemic PSO therapy and/or phototherapy~* Study participant agrees not to change their usual sun exposure during the course of the study and to use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs~* A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:~* Not a female of childbearing potential (FOCBP) OR A FOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 20 weeks after the last dose of study treatment~Exclusion Criteria:~* Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections~* Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection~* Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection~* Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer~* Study participant has a presence of active suicidal ideation or positive suicide behavior~* Study participant has a presence of moderately severe major depression or severe major depression~* Subject has a known hypersensitivity to any excipients of bimekizumab~* Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bimekizumab arm (Type: EXPERIMENTAL): Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
- Placebo arm (Type: PLACEBO_COMPARATOR): Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete